Single-Cell Polyfunctional Strength Applied to Checkpoint & Antibody Based Immunotherapies

Discover how polyfunctional strength is making an impact with bispecifics and combination checkpoint therapies

Unlock Webinar
[wpbb post:title]
Will Singleterry, PhD, Director of Business Development, IsoPlexis

  • Evaluate T cell responses induced by various bispecific T cell engagers across phenotypes

  • Understand the heterogeneity of TIL polyfunctionality in solid tumors in response to checkpoint inhibitors

  • Uniquely correlate clinical anti-tumor responses with IsoPlexis data

fierce innovation awards
red dot award
the scientist top 10 innovation award
2021-04-27T23:19:03-04:00